tbuckley/cabot-search huggingface dataset:
Abstract 2062: Nanoemulsion formulations for anticancer agent piplartine characterization, toxicological, pharmacokinetics and efficacy studies
Authors: Neel Fofaria, Alok Ranjan, Hussaini Syed Sha Qhattal, Xinli Liu, Sanjay K. Srivastava
Journal: Cancer Research (2016)

Abstract Piplartine (PL) is an alkaloid found in black-pepper and known for its anticancer activity, however, due to poor solubility and lack of proper formulation, its use for oral administration is a challenge. The objective of this study was to formulate PL into nanoemulsion drug delivery system for oral delivery and thereafter evaluate toxicity, pharmacokinetics and therapeutic efficacy. Optimized nanoemulsions were formulated by self-emulsification as well as by homogenization-sonication method. Two nanoemulsions enhanced the solubility of PL with low polydispersity index and high stability. Both PL loaded nanoemulsions exhibited enhanced dissolution, cellular permeability and cytotoxic effects as compared to pure PL. Formulation of PL into nanoemulsions did not obstruct its cellular uptake in cancer cells. Blank or PL loaded nanoemulsions did not exhibited toxicity in mice upon daily oral administration for 60 days. Pharmacokinetics of PL followed a two-compartment model after intravenous administration. PL loaded nanoemulsions showed 1.5-fold increase in oral bioavailability as compared to free PL. Finally, PL loaded nanoemulsions showed marked anti-tumor activity at a dose of 10 mg/kg in melanoma tumor bearing mice. In conclusion, for the first time we have developed a stable nanoemulsion delivery system for oral administration of PL, which enhanced its solubility, oral bioavailability and anti-tumor efficacy. Citation Format: Neel Fofaria, Alok Ranjan, Hussaini Syed Sha Qhattal, Xinli Liu, Sanjay K. Srivastava. Nanoemulsion formulations for anticancer agent piplartine characterization, toxicological, pharmacokinetics and efficacy studies. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2062.
ROL DE LAS PRÓTESIS EN EL TRATAMIENTO DE ESTENOSIS BENIGNAS CERVICALES ESOFÁGICAS
Authors: A Clemente Sánchez, Ó Nogales Rincón, A Caballero Marcos, MD Pérez Valderas, J García Lledó, M López Ibáñez, B Merino Rodríguez, L Pérez Carazo, C González Asanza
Journal: Endoscopy (2015)

Las estenosis esofágicas benignas son un problema habitual en endoscopia. El tratamiento estándar es la dilatación endoscópica, no obstante, un 10 – 15% son refractarias (no respondedoras/recurrentes), proponiéndose, entre otros, el manejo mediante prótesis esofágicas. La localización cervical de la estenosis supone una dificultad añadida, existiendo escasa literatura al respecto.
Abstract 5034: Overexpression of MYST4 induces tumor progression in hepatocellular carcinoma
Authors: Tsui Lien Mao, Jinn-Chyuan Sheu
Journal: Cancer Research (2016)

Abstract MYST4 is a member of histone acetyltransferases which are involved in transcriptional activation of genes important for cellular growth and development. Our previous study revealed that overexpression of MYST4 in ovarian high-grade serous carcinoma correlated with worse survival. To further explore the role of MYST4 in human cancers, we selected hepatoma cell line Huh 7 due to its high level of MYST4 expression among various cancer cell lines tested. Immunohistochemical study showed that overexpression of MYST4 correlated with worse overall survival in hepatoceullular carcinoma (P = 0.02). Furthermore, tumor cells at invasion front and in lymphovascular spaces are frequently overexpressed. Knockdown of MYST4 in Huh 7 resulted in significantly reduced cellular growth, migration and perturbed cell cycle progression. Mouse xenograft model revealed that MYST4-knockdown Huh 7 cells had lower growth rate, consistent with the in vitro findings. Together, our studies suggest that MYST4 promotes cell growth, migration and lymphovascular spread in hepatocellular carcinoma. Thus, MYST4 may serve as a druggable target in treating hepatocellular carcinoma. Citation Format: Tsui Lien Mao, Jinn-Chyuan Sheu. Overexpression of MYST4 induces tumor progression in hepatocellular carcinoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5034.
Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma,
Authors: Shatha Farhan, Heather Lin, Veerabhadran Baladandayuthapani, Nina Shah, Qaiser Bashir, Chitra M Hosing, Uday Popat, Simrit Parmar, Yvonne T Dinh, Sofia Qureshi, Gabriela Rondon, Sergio Giralt, Richard Champlin, Muzaffar H. Qazilbash
Journal: Blood (2011)
Abstract LB-176: The human androgen receptor regulates DNA damage response (DDR) in prostate cancer
Authors: Mohammad Asim, Heather Zecchini, Firas Tarish, Charlie Massie, Ajoeb Baridi, Anne Warren, Wanfeng Zhao, Leigh-Anne McDuffus, Patrice Mascalchi, Greg Shaw, Harveer Dev, Karan Wadhwa, Paul Wijnhoven, Josep Forment, Scott Lyons, Andy Lynch, Cormac O’Neill, Vincent Zecchini, Paul Rennie, Aria Baniahmad, Simon Tavare, Ian Mills, Niklas Schulz, Yaron Galanty, Thomas Helleday, David Neal
Journal: Cancer Research (2016)

Abstract Clinical studies have shown the improved benefit of combining androgen deprivation therapy (ADT) with radiotherapy, indicating a potential interaction between the androgen signalling and DNA damage response (DDR) pathways in PCa. We have explored the underlying basis of this interaction by interrogating the mechanism of androgen regulation of the DDR in men with PCa, both untreated and treated with an androgen inhibitor. We show that androgen receptor (AR) signalling regulates the DDR and promotes DDR foci formation leading to ATM activation in PCa. Our data showing that AR regulates DDR provides an explanation for the improved outcome of combined ADT and radiotherapy. Thus, our work identifies the rationale for targeting both the AR and DDR pathways simultaneously to improve therapy outcome in advanced or high risk prostate cancer. Citation Format: Mohammad Asim, Heather Zecchini, Firas Tarish, Charlie Massie, Ajoeb Baridi, Anne Warren, Wanfeng Zhao, Leigh-Anne McDuffus, Patrice Mascalchi, Greg Shaw, Harveer Dev, Karan Wadhwa, Paul Wijnhoven, Josep Forment, Scott Lyons, Andy Lynch, Cormac O’Neill, Vincent Zecchini, Paul Rennie, Aria Baniahmad, Simon Tavare, Ian Mills, Niklas Schulz, Yaron Galanty, Thomas Helleday, David Neal. The human androgen receptor regulates DNA damage response (DDR) in prostate cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-176.
Abstract 5072: Paracrine interactions between Schwann cells and cancer cells promotes perineural invasion via L1cam secretion
Authors: Shorook Na’ara, Ziv Gil, Moran Amit
Journal: Cancer Research (2016)

Abstract Cancerous neural invasion (CNI) is a well-known route of cancer spread in head and neck cancer. Patients with CNI suffer from severe morbidity due to neuropathic pain and most succumb to cancer within months. The exact mechanism that drives cancer cells to disseminate along nerves remained to be defined. The overall objective of our research was to identify candidate proteins and host cells that contribute to CNI. L1 cell adhesion molecule (L1cam) is a 200kDa transmembrane glycoprotein of the immunoglobulin superfamily. In many human cancers, L1cam is constitutively over-expressed, and its expression is generally associated with poor prognosis and metastases formation. Immunohistochemical analysis of the neural niche in human cancer specimens showed overexpression of L1cam in both cancer cells and Schwann cells. To address the role of L1cam in vitro, we used the Dorsal Root Ganglia. Treatment of Cancer Cells with Anti L1cam mAb resulted in a significant reduction in CNI of cancer cells. Next, we used Schwann cells conditioned media (SCCM) to study the role of soluble Schwann cells derived L1cam. Immunopercipitation of L1cam in SCCM resulted in a significant reduction in L1cam concentration and led to reduced cancer cell migration, invasion, and motility. To study the role of SCCM as a chemo attractant to cancer cells we utilized a modified in-vitro nerve invasion assay that consists of 3 layers Fibroblasts-ECM-Schwann. In this model blocking the activity of L1cam in Schwann cells inhibited the cancer cells invasion through these layers. Finally, in-vivo studies in transgenic mice treated with L1cam mAb triweekly, showed a significant reduction in CNI in the tumors compared to the control group. Taken together, our results identify a paracrine interaction between Schwann cells in the neural niche and the cancer cells promotes perineural invasion via L1cam secretion. Citation Format: Shorook Na’ara, Ziv Gil, Moran Amit. Paracrine interactions between Schwann cells and cancer cells promotes perineural invasion via L1cam secretion. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5072.
P208 Take up of industrial injuries disablement benefits and spirometric pattern on subjects with asbestos related diffuse pleural thickening (DPT): Abstract P208 Table 1.
Authors: S Gudur, J Hoyle
Journal: Thorax (2013)

<h3></h3> Industrial injuries disablement benefit (IIDB) defines asbestos related diffuse pleural thickening (DPT) with obliteration of a costophrenic angle on chest x-ray as eligible for compensation. Previous studies report significant airflow limitation and functional impairment in these patient. <h3>Methods</h3> A database search from 08/2005 to 01/2013 for DPT as agreed by a multi-disciplinary team meeting as fulfilling the criteria for a claim. Any IIDB advice given, records of those who applied, smoking history and lung function tests at presentation were interrogated. Lung function was performed by a specialist cardio-pulmonary technician by body plethysomography. Airflow obstruction defined by ARTP/BTS criteria as FEV1/ FVC &lt;70% and severity of airflow obstruction by FEV1 (50–80% predicted as mild, 30–49% predicted as moderate and &lt;30% as severe obstruction respectively). <h3>Results</h3> 39/50 male subjects with DPT attended follow-up. 100% were given written advice of their eligibility to claim IIDB. 24/39 (62%) who were followed up applied for IIDB, with disability ranging from 15 - 100%. 2 were recorded as having less than 15% disability. Of 15 who did not apply, 4 patients’ exposure was not work related and 11 chose not to apply. 4/39 (10%) were never smokers and 30/39 (77%) ex-smokers. Lung function results were available for 43/50 at presentation (table 1). <h3>Conclusions</h3> Our group of patients had a significantly high smoking history. Airflow limitation with DPT is the predominant lung function abnormality seen. Despite their disability, patients chose not to apply for IIDB as above. The airflow limitation may be progressive and hence important to repeat the lung function tests over a time period to see if this deteriorates further contributing to worsening disability. <h3>References</h3> Abnormal lung function associated with asbestos disease of the pleura, lung and both; comparitive analysis, <i>Thorax</i> 1991.
Abstract 926: Pentraxin 3 is responsive to the activation of CCAAT/enhancer binding delta and promotes cancer progression in the tumor microenvironment
Authors: Jhih-Ying Chi, Ju-Ming Wang
Journal: Cancer Research (2016)

Abstract This lack of understanding especially impacts the design of anticancer treatments. It is a common observation in the clinic that recurrent cancers, and particularly anticancer drug-resistant cancers, are more difficult to treat because they spread faster than the original tumor. CCAAT/enhancer binding protein delta (CEBPD) was activated in M2 macrophages and myofibroblasts/cancer-associated fibroblasts (CAFs) and contributed to metastasis, invasion and recurrence of cancer cells in response to PGE2 and the anticancer drugs. We further found that pentraxin 3 (PTX3) was activated in response to CEBPD induction and involved in migration and invasion of breast cancer cells, and the same phenomenon was also observed in drug-resistant cancers. Interestingly, we found that a recombinant PTX3 protein containing the C-terminal region (pPTX3) showed an opposite tumorigenic effect to the mammalian PTX3. The results suggest that PTX3 could be a promising target for preventing the metastasis/invasion of cancers and treating drug-resistant cancers. Citation Format: Jhih-Ying Chi, Ju-Ming Wang. Pentraxin 3 is responsive to the activation of CCAAT/enhancer binding delta and promotes cancer progression in the tumor microenvironment. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 926.
Piecemeal degranulation of mast cells in the inflammatory eyelid lesions of interleukin-4 transgenic mice. Evidence of mast cell histamine release in vivo by diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry
Authors: AM Dvorak, RI Tepper, PF Weller, ES Morgan, P Estrella, RA Monahan-Earley, SJ Galli
Journal: Blood (1994)
Uncontrolled Hypertension and Risk of Cardiovascular Mortality in China
Authors: Donghao Zhou, Shiming Wang, Tao Tian
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 2301: Intraperitoneal CAR-T infusion results in durable protection against peritoneal metastases and control of systemic tumor growth
Authors: Marissa Cunetta, Gary Point, Zhi Liu, Prajna Guha, Josephine Darpolor, Matthew Lima, N J. Espat, Nader Hanna, Cherif Boutros, Richard P. Junghans, Steven Katz
Journal: Cancer Research (2016)

Abstract Colorectal carcinomatosis due to peritoneal metastases (PM) is a significant cause of morbidity and mortality. Present treatments fail to cure the majority of patients with PM. We are developing a chimeric antigen receptor T cell (CAR-T) regional infusion immunotherapy platform for PM. We treated mice with established CEA+ MC38 PMs with anti-CEA CAR-Ts either via regional intraperitoneal (IP) or systemic tail vein (TV) infusion. When compared to TV infusion, IP delivery resulted in significantly improved responses (37-fold reduction in tumor growth, p&amp;lt;0.01). To measure the durability of protection from IP tumor growth, we re-challenged mice with IP tumor following successful treatment with IP CAR-Ts. Mice who had received initial IP CAR-T treatment were protected from tumor growth following re-challenge for 20 days compared to control animals (1390-fold reduction in tumor growth, p = 0.016). Assessment of IP tumor 10 and 28 days following tumor re-challenge revealed a high proportion of intratumoral CAR-Ts (Day 10- 70.0%, Day 28- 46.6%; p = 0.10) and the proportion of CAR-Ts with an effector memory phenotype (CD44+CD62L-CCR7-, Day 10- 19.3%, Day 28- 60.0%; p&amp;lt;0.01). In separate experiments, we studied the effect of IP CAR-T infusions on tumor growth at distant sites. We established both IP and subcutaneous (SQ) flank tumors in mice prior to CAR-T infusions. Following treatment, IP CAR-T infusion resulted in a significant decrease in SQ tumor growth on day 8 compared to control (5.7-fold, p = 0.03), and a trend toward improvement compared to TV (4.9-fold, p = 0.224). While CAR-Ts were not detected in whole blood, SQ tumor, or draining lymph nodes following IP CAR-T infusion, serum IFNγ levels were significantly elevated on day 4 compared to control mice (p = 0.04), and returned to baseline by day 7. Our findings demonstrate that regional IP CAR-T delivery provides durable protection against IP tumor growth in association with CAR-T effector memory programming, in addition to a systemic anti-tumor effect. Citation Format: Marissa Cunetta, Gary Point, Zhi Liu, Prajna Guha, Josephine Darpolor, Matthew Lima, N J. Espat, Nader Hanna, Cherif Boutros, Richard P. Junghans, Steven Katz. Intraperitoneal CAR-T infusion results in durable protection against peritoneal metastases and control of systemic tumor growth. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2301.
구연 : B형 만성 간염 환자에서 라미부딘과 인터페론의 병합요법이 Viral Breakthrough의 출현에 미치는 영향
Authors: 장명국, 정영화, 김정아, 최민희, 신정우, 류수형, 김인숙, 김성훈, 최원범, 임영석, 이한주, 이영상, 서동진
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 라미부딘은 B형 만성 간염환자들에 대한 항바이러스 요법으로 그 효과가 입증되어 널리 사용되고 있으나, 장기간 투여시 특히 YMDD 돌연변이종의 출현으로 인해 viral breakthrough가 흔히 발생하는 것으로 알려져 있다. 이에, 라미부딘의 장기 투여시 라미부딘과 인터페론의 병합 요법이 viral breakthrough의 출현에 미치는 영향을 평가하고자 하였다. 대상과 방법: 혈청 HBeAg와 HBV-DNA가 양성이고 혈청 ALT치가 정상 상한치의 2배 이상이며 간조직 생검상 B형 만성 간염으로 진단된 환자들 중, 인터페론 요법(인터페론 알파 2b, 5MU, 주 3회, 피하 주사)에도 불구하고 최소한 4개월 이상 연속적으로 혈청 HBV-DNA가 양성인 환자 83예를 대상으로 하였다. 대상 예들은 무작위로 라미부딘 단독(LAM군; n＝41) 혹은 라미부딘과 인터페론 병합요법(LAM/IFN군; n＝42)을 시행받았다. LAM/IFN군에서 인터페론은 6개월간 혈청 HBV-DNA가 음성을 유지하거나 viral breakthrough가 출현할 때까지 추가로 투여하였다. 라미부딘은 매일 100mg을 최소한 12개월 이상 투여하였다. 경과 관찰 중 1-2개월 간격으로 검사한 HBV DNA가 2회 이상 연속적으로 양성인 경우를 viral breakthrough로 정의하였다. 결과: 1) 분석 대상이 되었던 74예들에서 (LAM군 39예, LAM/IFN군 35예) 양군간 성별, 연령, 혈청 ALT, HBV-DNA치 및 조직학적 중증도에 차이가 없었다. 2) 경과 관찰 중 혈청 HBV-DNA의 음전율 및 혈청 ALT치의 정상화율에도 양군간 차이를 보이지 않았다. 3) 12, 24 및 36개월 후 혈청 HBeAg의 음전율은 LAM군과 LAM/IFN군에서 각각 30.8%, 38.9% 및 41.9%와 48.6%, 61.4% 및 66.9%로서 LAM/IFN군에서 높은 경향을 나타냈다(p＝0.07) 4) LAM군과 LAM/IFN군에서 viral breakthrough의 출현율은 12, 24 및 36개월에 각각 10.3%, 56.5% 및 59.4%와 5.7%, 22.4% 및 32.1%로 LAM/IFN군에서 유의하게 낮았다(p＜0.01). 5) Viral breakthrough를 보인 환자 31예들 중 YMDD 영역의 돌연변이는 LAM군과 LAM/IFN군에서 각각 군의 82%(18/22) 및 56%(5/9)에서 관찰되었다. (p＝0.19) 결론: 라미부딘의 장기 투여시 라미부딘과 인터페론의 병합 요법은 viral breakthrough의 출현을 감소시킬 수 있을 것으로 생각된다.
Abstract 1679: Notch4 mediates mesenchymal-epithelial-like transition in melanoma
Authors: Ehsan BonyadiRad, Heinz Hammerlindl, Dinoop Ravindran Menon, Christine Hafner, Meenhard Herlyn, Helmut Schaider
Journal: Cancer Research (2016)

Abstract In melanoma Notch signaling is a well-established oncogenic factor and presumably driver of disease progression. Here we report that overexpression of the constitutively active intracellular domain of Notch4 (N4ICD) directs a mesenchymal-epithelial-like transition that results in an epithelial, low migratory, invasive and proliferative phenotype with decreased tumorigenicity in-vivo. Investigating the expression profile of 50 EMT markers in N4ICD overexpressing cells revealed an epithelial-like gene signature with major EMT markers, including Vimentin, MMP2, Snail1, Snail2 and Twist1, significantly decreased and several epithelial markers, including E-cadherin, Desmoplakin and Occludin significantly increased. N4ICD suppresses the expression of Snail2 and Twist1 in a non-canonical fashion by inducing transcription factors Hey-1 and Hey-2 which directly bind to promoter regions of Snail2 and Twist1 as determined by EMSA and luciferase assays. N4ICD overexpression also results in increased beta-catenin protein levels exclusively limited to the cytoplasm. Immunohistochemical stainings of primary melanomas and subcutaneous metastasis showed a correlation between Notch4, E-cadherin and beta-catenin expression. Our results demonstrate that overexpression of Notch4 ICD results in the emergence of an epithelial-like phenotype with increased E-cadherin and cytoplasmic beta catenin potentially steering the reformation of adherens junctions. This indicates that Notch4 supports a mesenchymal-epithelial-like transition trapping cancer cells in a low proliferative, invasive and migratory epithelial state, suggesting Notch4 to be a tumor suppressor in melanoma. Citation Format: Ehsan BonyadiRad, Heinz Hammerlindl, Dinoop Ravindran Menon, Christine Hafner, Meenhard Herlyn, Helmut Schaider. Notch4 mediates mesenchymal-epithelial-like transition in melanoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1679.
Are Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease “Separate but Equal”?
Authors: John M. Ringman
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Second Cancers after Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma (NHL).
Authors: Tara Seshadri, Melania Pintilie, Richard Tsang, John Kuruvilla, Sahar Zadeh, Armand Keating, Michael Crump
Journal: Blood (2007)